July 2022
Price: £95 PLUS VAT
Format: DOWNLOADABLE PDF
This conference examined key issues for medicine regulation, looking at next steps for clinical trials and patient involvement.
Overall, key areas for discussion included:
- regulation - the MHRA’s Delivery Plan for 2021-23 - the evolving role and scope of the regulator - developing new approaches to regulation - partnerships
- clinical trials - priorities for change following consultation - public involvement - efficiency - transparency - issues for ensuring patients are listened to and responded to as part of the process
- innovation - regulatory support - developing frameworks to facilitate safe access to innovative products and new therapies - options for streamlining and fast-track approvals
- wider priorities - evidence collection - improving health outcomes - engagement with the wider life sciences ecosystem - the UK’s international role
We are pleased to have been able to include keynote sessions with Dr Glenn Wells, Chief Partnerships Officer, MHRA; Juliet Tizzard, Director of Policy and Partnerships, Health Research Authority; Dr Ali Hansford, Head of Regulatory Strategy Policy, ABPI; and Meindert Boysen, Director, Centre of Health Technology Evaluation, NICE.
The conference was an opportunity for stakeholders to consider the issues alongside key policy officials who attended from the DHSC; Department of Health, NI; DIT; MHRA; GLD; OLS; and The Scottish Government - as well as by parliamentary pass-holders from the House of Lords.
